Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Analysis of Body Surface Area Involvement in the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2022, 6 (6), s45. https://doi.org/10.25251/skin.6.supp.45.